FDA Lifts Pause on Chikungunya Vaccine IXCHIQ Use in Adults 60+ Following Safety Review
Published: August 8th 2025 | Updated: August 8th 2025After a three-month review, the FDA and EMA have cleared continued use of IXCHIQ in adults 60+, adding new safety warnings for elderly individuals with chronic conditions.
Determining Resistance Patterns in Difficult-to-Treat Resistant Pseudomonas Infections
August 5th 2025Results from a recent study comparing ceftolozane-tazobactam and ceftazidime-avibactam for difficult-to-treat Pseudomonas aeruginosa infections found no statistically significant difference in resistance emergence but a surprising numerical trend favoring ceftazidime-avibactam. Pranita Tamma, MD, MHS, continues her conversation about this topic.
FDA Fast Tracks Antibody Therapy for Pulmonary Infections Including Cystic Fibrosis
Published: August 5th 2025 | Updated: August 5th 2025Clarametyx Biosciences said its investigational antibody therapy, CMTX-101, which is in a phase 1b/2a study, remains on track for full trial enrollment by the end of 2025.
Dialysis Facility Responses to Candida auris Exposure in Four US States From 2020–2023
August 4th 2025Tennessee, New Jersey, North Carolina, and South Carolina were evaluated by Alexandra Kurutz, MPH, and Simone Godwin, DVM, MPH, MS, CIC, in a review of C auris containment efforts in dialysis facilities using standard IPC measures.
What Role Should Scientists, Clinicians Play With Mirror Life Policy, Public Communication
August 4th 2025In part 2 of the conversation, David Relman, MD, discusses the importance of the research and medical communities in shaping future work in this area as well as the potential severe consequences of Mirror Life in a worse case scenario.
Understanding the Serious Risks, Potential Benefits Around the Mirror Life Concept
August 3rd 2025David Relman, MD, discusses the theoretical issues of "mirror life," how the scientific community could potentially research natural chirality synthetic life, and how mirror molecules may be a way to extract beneficial research from the concept.
Investigational Celiac Treatment Found Safe, Effective for Children with Severe Post-Covid Syndrome
July 30th 2025Study investigators found a therapy designed to treat Celiac disease supported a more rapid return to normal activities for patients with multisystem inflammatory syndrome in children (MIS-C).